These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 28319417)
1. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis. Trenova AG; Slavov GS; Manova MG; Draganaova-Filipova MN; Mateva NG; Miteva LD; Stanilova SA Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417 [TBL] [Abstract][Full Text] [Related]
2. Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis. Trenova AG; Manova MG; Kostadinova II; Murdjeva MA; Hristova DR; Vasileva TV; Zahariev ZI Folia Med (Plovdiv); 2011; 53(2):29-35. PubMed ID: 21797104 [TBL] [Abstract][Full Text] [Related]
3. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis. Trenova AG; Slavov GS; Manova MG; Kostadinova II Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430 [TBL] [Abstract][Full Text] [Related]
4. Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis. Trenova AG; Slavov GS; Draganova-Filipova MN; Mateva NG; Manova MG; Miteva LD; Stanilova SA Neurol Res; 2018 Mar; 40(3):153-159. PubMed ID: 29297273 [TBL] [Abstract][Full Text] [Related]
5. An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β. Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A CNS Neurol Disord Drug Targets; 2015; 14(6):804-10. PubMed ID: 25801840 [TBL] [Abstract][Full Text] [Related]
6. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β. Bălaşa R; Bajko Z; Huţanu A Mult Scler; 2013 Jun; 19(7):885-90. PubMed ID: 23207971 [TBL] [Abstract][Full Text] [Related]
7. Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing-Remitting-Multiple Sclerosis Patients. D'Angelo C; Reale M; Costantini E; Di Nicola M; Porfilio I; de Andrés C; Fernández-Paredes L; Sánchez-Ramón S; Pasquali L Front Immunol; 2018; 9():1240. PubMed ID: 29915590 [TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis. Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369 [TBL] [Abstract][Full Text] [Related]
9. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels. Babaloo Z; Aliparasti MR; Babaiea F; Almasi S; Baradaran B; Farhoudi M Immunol Lett; 2015 Apr; 164(2):76-80. PubMed ID: 25625963 [TBL] [Abstract][Full Text] [Related]
10. Assessment of CCL27 and IL-11 in Multiple Sclerosis Patients Treated with Interferon-β and Glatiramer Acetate. Ebrahimi Monfared M; Shapoori S; Mosayebi G; Khansarinejad B; Ghazavi A; Rezagholizamenjany M; Ganji A Neuroimmunomodulation; 2019; 26(6):301-306. PubMed ID: 31935737 [TBL] [Abstract][Full Text] [Related]
11. Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response. Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A; Tilea B; Tiu C CNS Neurol Disord Drug Targets; 2017; 16(1):93-101. PubMed ID: 27306062 [TBL] [Abstract][Full Text] [Related]
12. Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients. Ganji A; Monfared ME; Shapoori S; Nourbakhsh P; Ghazavi A; Ghasami K; Mosayebi G Cytokine; 2020 Feb; 126():154911. PubMed ID: 31731047 [TBL] [Abstract][Full Text] [Related]
18. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients. Ziemssen T; Calabrese P; Penner IK; Apfel R J Neurol; 2016 Apr; 263(4):784-91. PubMed ID: 26914926 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. Hernandez L; Guo S; Kinter E; Fay M J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984 [TBL] [Abstract][Full Text] [Related]
20. Serum Levels of Biomarkers of Immune Activation and Associations With Neurological Impairment in Relapsing-Remitting Multiple Sclerosis Patients During Remission. Witkowska AM; Socha K; Kochanowicz J; Karpińska E; Jakoniuk M; Zujko ME; Wilkiel M; Borawska MH; Mariak Z Biol Res Nurs; 2016 Jan; 18(1):113-9. PubMed ID: 25911236 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]